Erythrocin IV 1g powder for injection vial

দেশ: অস্ট্রেলিয়া

ভাষা: ইংরেজি

সূত্র: Department of Health (Therapeutic Goods Administration)

সক্রিয় উপাদান:

erythromycin lactobionate, Quantity: 1515 mg (Equivalent: erythromycin, Qty 1 g)

থেকে পাওয়া:

Amdipharm Mercury Australia Pty Ltd

INN (আন্তর্জাতিক নাম):

Erythromycin lactobionate

ফার্মাসিউটিকাল ফর্ম:

Injection, powder for

রচনা:

Excipient Ingredients:

প্রশাসন রুট:

Intravenous

প্যাকেজ ইউনিট:

1g X 1

শ্রেণী:

Medicine Registered

প্রেসক্রিপশন টাইপ:

(S4) Prescription Only Medicine

থেরাপিউটিক ইঙ্গিত:

INDICATIONS AS AT 1 November 2002: Oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. Erythrocin-I.V. (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections caused by Streptococcus pyogenes (Group A beta-haemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower respiratory tract infections caused by Streptococcus pyogenes (Group A beta-haemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria - As an adjunct to diphtheria antitoxin in infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: Erythrocin-I.V. (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for T. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease.

পণ্য সারাংশ:

Visual Identification: White powder; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

অনুমোদন অবস্থা:

Licence status A

অনুমোদন তারিখ:

2006-12-04

তথ্য লিফলেট

ERYTHROCIN
® IV
_erythromycin 1 g (as lactobionate)_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about ERYTHROCIN IV.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
nurse.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you being given
ERYTHROCIN IV against the
benefits they expect it will have for
you.
IF YOU HAVE ANY CONCERNS ABOUT
BEING GIVEN THIS MEDICINE, ASK YOUR
DOCTOR OR NURSE.
KEEP THIS LEAFLET.
You may need to read it again.
WHAT ERYTHROCIN IV
IS USED FOR
ERYTHROCIN IV contains
erythromycin, an antibiotic that
belongs to the group of medicines
called macrolides. These medicines
work by killing or stopping the
growth of bacteria that cause
infections.
ERYTHROCIN IV is used to treat
certain bacterial infections. These
infections may occur in different
parts of the body.
ERYTHROCIN IV will not work
against infections caused by viruses,
such as colds or flu.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY THIS MEDICINE
HAS BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed it
for another reason.
This medicine is available only with
a doctor's prescription.
BEFORE YOU ARE GIVEN
ERYTHROCIN IV
TELL YOUR DOCTOR IF YOU HAVE ANY OF
THE FOLLOWING CONDITIONS OR IF YOU
HAVE EVER EXPERIENCED ANY OF THESE
CONDITIONS.
It is very important that your doctor
is aware of these matters when
determining whether or not to
prescribe ERYTHROCIN IV.
_WHEN YOU MUST NOT BE GIVEN_
_ERYTHROCIN IV_
YOU MUST NOT BE GIVEN
ERYTHROCIN IV IF YOU HAVE AN
ALLERGY TO:
•
any medicine containing
erythromycin
•
any of the ingredients listed at the
end of this leaflet
•
other antibiotics from the
macrolide family, including:
-
clarithromycin
-
roxithromycin
Some of the symptoms of an allergic
reaction may include:
•
shortness of breath
•
wheezing or difficulty breathing
•
swelling of the face, lips, tongue
or other parts of the body
•
rash, itching or hives on the skin.
•
you have

পণ্য বৈশিষ্ট্য

ERYTHROCIN
® IV
1
AUSTRALIAN PRODUCT INFORMATION
ERYTHROCIN
® IV
ERYTHROMYCIN (AS LACTOBIONATE)
POWDER FOR INJECTION
1
NAME OF THE MEDICINE
Erythromycin lactobionate
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Erythrocin IV (sterile erythromycin lactobionate) is a soluble salt of
erythromycin suitable
for intravenous administration containing the equivalent of 1 g
erythromycin activity.
Erythromycin is produced by a strain of
_Streptomyces erythraeus _
and belongs to the
macrolide group of antibiotics. It is basic and readily forms salts
with acids.
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Erythrocin IV (sterile erythromycin lactobionate) is available as a
sterile, lyophilized cake
for reconstitution.
4
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Oral erythromycin is not considered to be the antibiotic of choice in
severely ill patients.
Erythrocin IV (sterile erythromycin lactobionate) is indicated in the
treatment of infections
caused by susceptible strains of the designated organisms in the
diseases listed below when
oral administration is not possible or when the severity of the
infection requires immediate
high serum levels of erythromycin.
Intravenous
therapy should be replaced by oral
administration at the appropriate time.
•
Upper respiratory tract infections caused by
_Streptococcus pyogenes_
(Group A
beta-haemolytic
streptococci);
_Streptococcus _
_pneumoniae_
(
_Diplococcus _
_pneumoniae_
);
_Haemophilus influenzae_
(many strains of
_H. influenzae_
are not
susceptible to the erythromycin concentrations ordinarily achieved).
ERYTHROCIN
® IV
2
•
Lower respiratory tract infections caused by
_Streptococcus pyogenes _
(Group A
beta-haemolytic
streptococci);
_Streptococcus _
_pneumoniae _
_(Diplococcus _
_pneumoniae)_
.
•
Respiratory tract infections due to
_Mycoplasma pneumoniae._
•
Skin
and
skin
structure
infections
caused
by
_Streptococcus _
_pyogenes_
and
_Staphylococcus aureus_
(resistant staphylococci may emerge during treatment).
•
Dip